Credit Suisse’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-13,514
| Closed | -$263K | – | 3183 |
|
|
2023
Q2 | $263K | Buy |
13,514
+557
| +4% | +$13.2K | ﹤0.01% | 3036 |
|
|
2023
Q1 | $368K | Buy |
12,957
+1,093
| +9% | +$32.4K | ﹤0.01% | 2910 |
|
|
2022
Q4 | $347K | Buy |
11,864
+3,203
| +37% | +$102K | ﹤0.01% | 2964 |
|
|
2022
Q3 | $229K | Buy |
8,661
+154
| +2% | +$5.65K | ﹤0.01% | 3197 |
|
|
2022
Q2 | $378K | Sell |
8,507
-357
| -4% | -$16.4K | ﹤0.01% | 3025 |
|
|
2022
Q1 | $439K | Buy |
8,864
+174
| +2% | +$8.35K | ﹤0.01% | 3047 |
|
|
2021
Q4 | $443K | Buy |
8,690
+101
| +1% | +$5.23K | ﹤0.01% | 3903 |
|
|
2021
Q3 | $480K | Sell |
8,589
-1,417
| -14% | -$69.7K | ﹤0.01% | 3828 |
|
|
2021
Q2 | $428K | Sell |
10,006
-131
| -1% | -$5.41K | ﹤0.01% | 3928 |
|
|
2021
Q1 | $424K | Sell |
10,137
-9,297
| -48% | -$432K | ﹤0.01% | 3866 |
|
|
2020
Q4 | $906K | Sell |
19,434
-5,421
| -22% | -$254K | ﹤0.01% | 3401 |
|
|
2020
Q3 | $1.05M | Sell |
24,855
-393,237
| -94% | -$17.2M | ﹤0.01% | 2885 |
|
|
2020
Q2 | $20.1M | Buy |
418,092
+13,149
| +3% | +$656K | 0.01% | 946 |
|
|
2020
Q1 | $18.6M | Buy |
404,943
+162,826
| +67% | +$8.17M | 0.02% | 878 |
|
|
2019
Q4 | $14.5M | Buy |
242,117
+7,557
| +3% | +$451K | 0.01% | 1208 |
|
|
2019
Q3 | $13.3M | Buy |
234,560
+216,799
| +1,221% | +$12.2M | 0.01% | 1150 |
|
|
2019
Q2 | $989K | Buy |
17,761
+9,812
| +123% | +$512K | ﹤0.01% | 2941 |
|
|
2019
Q1 | $401K | Buy |
7,949
+353
| +5% | +$15.7K | ﹤0.01% | 3462 |
|
|
2018
Q4 | $305K | Sell |
7,596
-6,646
| -47% | -$342K | ﹤0.01% | 3510 |
|
|
2018
Q3 | $987K | Buy |
14,242
+1,511
| +12% | +$115K | ﹤0.01% | 2885 |
|
|
2018
Q2 | $963K | Buy |
12,731
+3,603
| +39% | +$227K | ﹤0.01% | 3032 |
|
|
2018
Q1 | $481K | Sell |
9,128
-929
| -9% | -$54K | ﹤0.01% | 3386 |
|
|
2017
Q4 | $537K | Sell |
10,057
-4,184
| -29% | -$233K | ﹤0.01% | 3399 |
|
|
2017
Q3 | $850K | Sell |
14,241
-5,915
| -29% | -$358K | ﹤0.01% | 3215 |
|
|
2017
Q2 | $1.59M | Sell |
20,156
-9,686
| -32% | -$792K | ﹤0.01% | 2382 |
|
|
2017
Q1 | $2.48M | Sell |
29,842
-6,060
| -17% | -$451K | ﹤0.01% | 2194 |
|
|
2016
Q4 | $2.85M | Buy |
35,902
+887
| +3% | +$64.4K | ﹤0.01% | 2135 |
|
|
2016
Q3 | $2.45M | Sell |
35,015
-6,919
| -16% | -$383K | ﹤0.01% | 2233 |
|
|
2016
Q2 | $1.63M | Sell |
41,934
-21,531
| -34% | -$897K | ﹤0.01% | 2507 |
|
|
2016
Q1 | $2.57M | Buy |
63,465
+57,771
| +1,015% | +$3.67M | ﹤0.01% | 2019 |
|
|
2015
Q4 | $505K | Buy |
5,694
+2,206
| +63% | +$174K | ﹤0.01% | 3373 |
|
|
2015
Q3 | $259K | Sell |
3,488
-7,740
| -69% | -$644K | ﹤0.01% | 3797 |
|
|
2015
Q2 | $908K | Sell |
11,228
-3,149
| -22% | -$205K | ﹤0.01% | 3275 |
|
|
2015
Q1 | $602K | Buy |
+14,377
| New | +$408K | ﹤0.01% | 3414 |
|
Other funds holding EGRX
BIP
Credit Suisse's EGRX Position: Q3 2023 in Review
Credit Suisse sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q3 2023, closing a stake of 13,514 shares — an estimated $263K sold.
Credit Suisse first reported a position in EGRX in Q1 2015 and held it in 34 quarters. The position peaked at $20.1M in Q2 2020. 107 funds tracked by Wall St. Rank hold EGRX as of Q3 2023.
- Credit Suisse reported no remaining Eagle Pharmaceuticals, Inc. position as of Q3 2023 after selling out during the quarter.
- Credit Suisse sold 13,514 Eagle Pharmaceuticals, Inc. shares in Q3 2023, an estimated $263K.
- Credit Suisse first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2015 and held it in 34 quarters.
- Credit Suisse's Eagle Pharmaceuticals, Inc. position peaked at $20.1M in Q2 2020.
- 107 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q3 2023.
Based on Credit Suisse's 13F filing for Q3 2023, filed 13 Nov 2023.